Literature DB >> 18338689

Leptospirosis: clinical presentation and correlation with serovars.

N Chidambaram1, M Ramanathan, V Anandi, S Sasikala, D J P Innocent, L Sarayu.   

Abstract

A total of 2400 patients with pyrexia of unknown origin and or suspected leptospirosis were included in this study. Dark field microscopy detected Leptospira in 690 cases, Leptospira serological Investigations proved positive in 570 out of these 690 patients. Among them 212 had the classical icteric and the other 358 had anicteric type of presentation. Notably eptospira interrogans serovar ictero haemorrhagiae infection was encountered in 212 patients. In 30 patients, who had multi organ dysfunction which included renal failure, hepatic dysfunction or meningitis was due to Leptospira interrogans Serovar cannicola. Coexsistense of leptospirosis and hepatitis B virus infection were noted in 15 patients. Antibody to Leptospira interrogans was demonstrated by Micro agglutination test (MAT) in addition to dark field microscopy positivity in these cases. Similarly HIV antibody was demonstrated in 30 of the 330 anicteric patients. 554 out of 570 cases responded to intra venous penicillin (216), and oral Doxycycline (182) and Augmentin (156), and the remaining 16 patients succumbed to death.

Entities:  

Mesh:

Year:  2007        PMID: 18338689

Source DB:  PubMed          Journal:  J Commun Dis        ISSN: 0019-5138


  2 in total

1.  InvA protein is a Nudix hydrolase required for infection by pathogenic Leptospira in cell lines and animals.

Authors:  Yihui Luo; Yan Liu; Dexter Sun; David M Ojcius; Jinfang Zhao; Xuai Lin; Dong Wu; Rongguang Zhang; Ming Chen; Lanjuan Li; Jie Yan
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

2.  Severe leptospirosis in hospitalized patients, Guadeloupe.

Authors:  Cecile Herrmann-Storck; Magalie Saint-Louis; Tania Foucand; Isabelle Lamaury; Jacqueline Deloumeaux; Guy Baranton; Maurice Simonetti; Natacha Sertour; Muriel Nicolas; Jacques Salin; Muriel Cornet
Journal:  Emerg Infect Dis       Date:  2010-02       Impact factor: 6.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.